title: Deferoxamine mesylate: a new hope for intracerebral hemorrhage: from bench to clinical trials.
abstract: Iron resulting from hemoglobin degradation is linked to delayed neuronal injury after intracerebral hemorrhage. Extensive preclinical investigations indicate that the iron chelator, deferoxamine mesylate, is effective in limiting hemoglobin- and iron-mediated neurotoxicity. However, clinical studies evaluating the use of deferoxamine in intracerebral hemorrhage are shortcoming. This article reviews the potential role of deferoxamine as a promising neuroprotective agent to target the secondary effects of intracerebral hemorrhage to limit brain injury and improve outcome, and ongoing efforts to translate the preclinical findings into clinical investigations.
authors.affiliation: Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA. mselim@bidmc.harvard.edu
authors.forename: Magdy
authors.initials: M
authors.lastname: Selim
mesh_terms: D000818:Animals; D002543:Cerebral Hemorrhage / Q000150:complications / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D003676:Deferoxamine / Q000627:therapeutic use*; D004195:Disease Models, Animal; D006454:Hemoglobins / Q000009:adverse effects; D006801:Humans; D009410:Nerve Degeneration / Q000209:etiology / Q000517:prevention & control; D017262:Siderophores / Q000627:therapeutic use*
chemical_list: D006454:Hemoglobins; D017262:Siderophores; D003676:Deferoxamine